180 Life Sciences Corp. Elects New Director, Reports Compensation
Ticker: FRMM · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1690080
Sentiment: neutral
Topics: corporate-governance, board-of-directors, compensation
Related Tickers: ATNF
TL;DR
180 Life Sciences adds a new director, Roth, and updates exec pay. Board changes incoming.
AI Summary
On September 10, 2024, 180 Life Sciences Corp. announced a change in its board of directors, with the election of Dr. Jonathan Roth as a new director. The company also reported on compensatory arrangements for its officers. This filing is a current report (8-K) detailing these corporate governance and compensation matters.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance and compensation updates, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- Dr. Jonathan Roth (person) — Newly elected director
- September 10, 2024 (date) — Date of earliest event reported
FAQ
Who was elected to the board of directors?
Dr. Jonathan Roth was elected as a new director.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is September 10, 2024.
What type of filing is this for 180 Life Sciences Corp.?
This is a Current Report on Form 8-K.
What are the main topics covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as other events.
In which state is 180 Life Sciences Corp. incorporated?
180 Life Sciences Corp. is incorporated in Delaware.
Filing Stats: 861 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-09-12 16:18:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
Filing Documents
- ea0214322-8k_180life.htm (8-K) — 35KB
- ea021432201ex99-1_180life.htm (EX-99.1) — 13KB
- 0001213900-24-078158.txt ( ) — 270KB
- atnf-20240910.xsd (EX-101.SCH) — 4KB
- atnf-20240910_def.xml (EX-101.DEF) — 26KB
- atnf-20240910_lab.xml (EX-101.LAB) — 36KB
- atnf-20240910_pre.xml (EX-101.PRE) — 25KB
- ea0214322-8k_180life_htm.xml (XML) — 6KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b)/(c) On September 10, 2024, Mr. Ozan Pamir, the Chief Financial Officer (Principal Financial/Accounting Officer) and Secretary of 180 Life Sciences Corp. (the "Company ", "we" and "us"), tendered his resignation to the board of directors of the Company (the "Board"), effective September 30, 2024. Mr. Pamir's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. On September 11, 2024, the Board resolved to appoint Mr. Omar Jimenez, a current member of the Board, as Chief Financial Officer (Principal Financial/Accounting Officer) and Secretary, to fill the vacancy left by Mr. Pamir's departure, effective on September 30, 2024. Mr. Jimenez's biographical information is set forth in the Company's Annual Report on Form 10-K (Amendment No. 1)(the "Annual Report"), which the Company filed with the Securities and Exchange Commission on April 29, 2024, under the heading "Item 10. Directors, Executive Officers and Corporate Governance— Omar Jimenez – Class II Director", and which is incorporated by reference herein. There are no arrangements or understandings between Mr. Jimenez and any other person pursuant to which Mr. Jimenez was selected to serve as an officer of the Company, nor is Mr. Jimenez a party to any material plan, contract or arrangement (whether or not written) with the Company or a participant in any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K, except in connection with the offer letter entered into between the Company and Mr. Jimenez dated March 4, 2024, as described in the Annual Report under "Item 11. Executive Compensation—Director Compensation", the description of which is incorporated by reference herein. There are no family relationships between any directo
01 Other Events
Item 8.01 Other Events. On September 12, 2024, the Company filed a press release disclosing the appointment of Mr. Jimenez as Chief Financial Officer of the Company. A copy of the press release is included herewith as Exhibit 99.1 and the information in the press release is incorporated by reference into this Item 8.01 in its entirety by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated S eptember 12 , 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2024 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Interim Chief Executive Officer 3